Silverarc Capital Management LLC Acquires 119,560 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Silverarc Capital Management LLC boosted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 82.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 264,560 shares of the biopharmaceutical company's stock after acquiring an additional 119,560 shares during the period. Celldex Therapeutics makes up approximately 1.5% of Silverarc Capital Management LLC's investment portfolio, making the stock its 24th largest holding. Silverarc Capital Management LLC owned 0.40% of Celldex Therapeutics worth $6,685,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC raised its holdings in Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 878 shares during the period. Headlands Technologies LLC acquired a new position in shares of Celldex Therapeutics during the 4th quarter worth approximately $81,000. KBC Group NV raised its position in Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares in the last quarter. AlphaQuest LLC lifted its stake in Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after acquiring an additional 2,705 shares during the last quarter. Finally, Aristides Capital LLC bought a new position in shares of Celldex Therapeutics in the 4th quarter valued at about $202,000.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. UBS Group initiated coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. The Goldman Sachs Group decreased their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Finally, Morgan Stanley initiated coverage on shares of Celldex Therapeutics in a research note on Thursday, March 20th. They set an "overweight" rating and a $46.00 target price for the company. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $54.33.

Celldex Therapeutics Stock Down 0.1 %

Shares of CLDX traded down $0.01 during mid-day trading on Friday, hitting $19.57. 377,561 shares of the company's stock were exchanged, compared to its average volume of 882,887. Celldex Therapeutics, Inc. has a 52 week low of $14.40 and a 52 week high of $47.00. The stock's 50-day simple moving average is $19.21 and its 200-day simple moving average is $23.49. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -7.61 and a beta of 1.59.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.